Introduction: Multiple myeloma (MM) is frequently associated with cardiac involvement, particularly myocardial amyloidosis. Current gold-standard diagnostic modalities include cardiac MRI, and endomyocardial biopsy. Speckle-tracking echocardiography (STE) enables detection of subclinical left ventricular dysfunction prior to overt structural or functional deterioration. This pilot retrospective study explored the association between GLS and clinically defined cardiac involvement in MM patients, in the absence of gold-standard confirmation. Methodology: We conducted a retrospective analysis of 20 consecutive MM patients, stratified into two groups: cardiac involvement (CI; n = 5) and non-cardiac involvement (Non-CI; n = 15). CI was defined using surrogate clinical criteria, documented heart failure and elevated NT-proBNP (age-specific) or unexplained interventricular septal thickness >12 mm. GLS was compared between groups, and the exploratory diagnostic performance of GLS was assessed using ROC analysis. A sensitivity analysis excluded patients who did not strictly meet the objective criteria. Results: Absolute GLS was significantly lower in the cardiac involvement group (median 9.6% vs. 16.9%, p = 0.007). GLS showed a promising area under the ROC curve of 0.980 (95% CI: 0.92–1.00) for identifying clinical cardiac involvement, with an optimal cut-off of −16% (sensitivity 100%, specificity 53.3%). All findings are preliminary due to the small sample size and lack of gold-standard confirmation. Conclusion: In this study, STE-derived GLS demonstrated promising diagnostic performance for identifying cardiac involvement in MM patients. However, given the small sample size, these findings should be considered hypothesis-generating. External validation in large, prospective, multi-center cohorts is required before any clinical implementation.

Research Background: Breast cancer is a malignant tumor that threatens women’s health. Among breast cancer patients, about 4.2% to 17% may suffer from multiple primary malignant neoplasms. Cases of patients suffering from both breast cancer and multiple myeloma are relatively rare in clinical practice. This paper reports one case of a patient who developed multiple myeloma during the treatment of breast cancer. Clinical Data: The patient was a 56-year-old female, admitted to hospital due to “fever for 4 days, one year after the treatment of left breast cancer”. The patient was diagnosed with left breast cancer (ypT1N1M0, HER2-overexpressing subtype) approximately one year prior to presentation. Following diagnosis, the patient was treated sequentially with TcbHP and THP chemotherapy regimens, and subsequently received local radiotherapy. The patient developed fever four days prior to admission. Further laboratory examinations revealed pancytopenia, positive IgA-λ-type monoclonal immunoglobulin by immunofixation electrophoresis, and myeloma cells accounting for 11% in bone marrow smears. Bone marrow immunophenotyping indicated abnormal plasma cells, and pathological results of bone marrow biopsy were consistent with multiple myeloma. The final diagnosis was breast cancer complicated with multiple myeloma. After confirmed diagnosis, the patient was transferred to another hospital for targeted treatment of multiple myeloma and has been receiving continuous treatment there up to the time of follow-up. Conclusions: For patients with breast cancer, if they develop bone pain, anemia, hypercalcemia or renal dysfunction that cannot be explained by tumor metastasis or conventional complications after surgery or during follow-up, clinicians should be alert to the possibility of second primary tumors.

Background: Acute lymphoblastic leukemia (ALL) with myocardial infiltration is a rare extramedullary manifestation, typically encountered in advanced or relapsed disease. Presentation as an isolated, reversible hypertrophic cardiomyopathy (HCM)-like phenotype without typical hematological symptoms is exceptional and poses a major diagnostic challenge. Case presentation: A 25-year-old man presented with fever, weight loss (20 kg over 3 months), progressive dyspnea, and bilateral lower extremity edema. Echocardiography and CMR imaging revealed severe asymmetrical left ventricular hypertrophy (maximum septal thickness 27 mm) with reduced left ventricular ejection fraction (as low as 27%), initially suggesting non-obstructive HCM. However, the presence of persistent fever, a marked inflammatory response (C-reactive protein 129 mg/L; reference: <10 mg/L), and elevated D-dimer and the lack of a family history or cardiovascular risk factors raised suspicion. Whole-body [ ¹⁸ F]FDG PET–CT demonstrated intense myocardial uptake (SUVmax 14.8) along with widespread lymphadenopathy and splenic involvement. Peripheral blood smear showed 23% lymphoblasts, and bone marrow examination confirmed T-cell acute lymphoblastic leukemia (T-ALL) with myeloid co-expression. Endomyocardial biopsy revealed diffuse infiltration by T-lymphoblastic cells (CD3 ⁺ , CD5 ⁺ , TdT ⁺ ). The patient received three cycles of chemotherapy (VDPL, venetoclax+chidamide+azacitidine, mitoxantrone+cytarabine). At follow-up after three cycles, bone marrow minimal residual disease was negative, and repeat echocardiography showed normalization of cardiac structure and function. Conclusion: This case illustrates that T-ALL can first manifest as a rapidly progressive, HCM-mimicking cardiomyopathy that is fully reversible with effective chemotherapy. Clinicians should suspect hematologic malignancy in a young patient with unexplained cardiac hypertrophy associated with constitutional symptoms, elevated inflammatory markers, and poor response to standard therapy for heart failure. Early bone marrow examination and, if necessary, endomyocardial biopsy can confirm the diagnosis.

Acquired dysfibrinogenemia is a rare and often underrecognized coagulation disorder characterized by impaired fibrinogen function rather than absolute defi

Objective: To evaluate the real-world efficacy and safety of golidocitinib in patients with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL). Methods: Clinical data of 3 patients with R/R PTCL treated with golidocitinib at our center between May 2024 and November 2025 were retrospectively analyzed. Baseline features, treatment regimens, responses, and adverse events (AEs) were collected and assessed. Results: Pathological subtypes included PTCL-not otherwise specified (PTCL-NOS, n=2) and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL, n=1). Following golidocitinib-based therapy, 2 patients achieved complete response (CR) and 1 partial response (PR), yielding an objective response rate (ORR) of 100%. Median follow-up was 6.2 months (range: 4.2–9.1 months); median progression-free survival (PFS) was not reached. Treatment-related AEs were predominantly hematological, mostly grade 1–2 and manageable. No treatment-related deaths occurred. Conclusion: Golidocitinib exhibits promising efficacy and a tolerable safety profile in R/R PTCL, including rare subtypes, supporting its role as a valuable therapeutic option. Larger cohorts are needed for further validation.

Background: Primary thyroid lymphoma (PTL) is a rare extranodal malignancy accounting for 1%–5% of all thyroid neoplasms, with diffuse large B-cell lymphoma (DLBCL) being the most common and aggressive subtype. Due to its low incidence, clinical data remain limited. This study aims to describe the clinical features, diagnostic approaches, treatment and outcomes of primary thyroid DLBCL in a single-center case series. Methods: We retrospectively enrolled four consecutive patients with histopathologically verified primary thyroid DLBCL who received treatment at our institution between 2021 and 2026. All relevant clinical data were extracted from archived electronic medical records. No statistical comparative analyses were performed given the limited sample size. Results: The cohort comprised four females, with a mean age of 73.5 years (range, 50–88 years). All patients presented with a rapidly enlarging painless neck mass, and two (50%) exhibited compressive symptoms. Elevated thyroid autoantibodies (TPO-Ab and/or TG-Ab) were detected in three patients (75%), indicating underlying Hashimoto’s thyroiditis. Diagnostic procedures varied among individuals: fine-needle aspiration cytology (FNAC) and/or core-needle biopsy (CNB), partial thyroidectomy were applied for pathological confirmation. All cases were classified as DLBCL. One patient received R-CHOP immunochemotherapy, one received Pola-R-CHP, and two opted for observation management. Conclusion: This case series provides descriptive real-world observations of primary thyroid DLBCL among elderly Chinese with underlying Hashimoto’s thyroiditis. Findings from this small cohort cannot be generalized. Immunochemotherapy regimens including R-CHOP and Pola-R-CHP may be considered within individualized multidisciplinary strategies; further large-scale studies are required to validate therapeutic performance.